Holy cow, Ray! There's biotechs all over your scans. We gotta get Rick Harmon in here, to help sort this out. After the Entremed story last weekend and rocket on Monday, the big move in $BTK biotech index was today, up 4.1%. Artificial skin in Forbes, a whole issue of Discover devoted to biotech; $BTK is with half a point of its 1998 high. Laissez les bons temps roulez!
Biotechs in your scans tonight include all of these, many on multiple lists: AKRN, CYTO, NSTK, RIBI, SCIO, UMED, CVAS, NEOT, ATIS, DERM, IMCL, NERX, BIPL, ISIP, QDEL, and TRGA.
CYTO has two approved products, to which they sold many rights on the way there. Did they sell the farm on the way to market? Or at this low price, have they become a bargain?
NSTK has technology to nasally deliver drugs, avoiding destruction in the digestive system, and applying medicines directly to the inflamed or affected tissue in nasal passages or lungs. There was a mention of the technology today on Marketplace on NPR.
IMCL was on the list last weekend of possible ENMD sympathy plays. ISIP has an antisense technology that may attract attention in cancer.
AKRN, as you know, is a long-term holding for me, and it announced launch of a new product today (5 of them this year). If you traders want to take it for a ride, that's fine with me, though I'll probably just hold it -:) Don't worry about the P/E of 42; the growth rate is much higher than that.
Lots more stocks on the scans! The talking heads on CNBC have been going off on them all week, cluelessly, IMHO. Let's ask Rick. |
